Cluster Headache Characteristics and the Severity of Obstructive Sleep Apnea: Insights from Polysomnography Analysis

Yooha Hong; Mi-Kyoung Kang; Min Kyung Chu; Soo-Jin Cho; Hee-Jin Im

doi:10.62087/hpr.2024.0001

Articles

Page Path: HOME > Headache Pain Res > Volume 25(1); 2024 > Article

Original Article Cluster Headache Characteristics and the Severity of Obstructive Sleep Apnea: Insights from Polysomnography Analysis: Yooha Hong¹, Mi-Kyoung Kang¹, Min Kyung Chu², Soo-Jin Cho¹, Hee-Jin Im¹; Headache and Pain Research 2024;25(1):63-71.
DOI: https://doi.org/10.62087/hpr.2024.0001
Published online: April 16, 2024

¹Department of Neurology, Dongtan Sacred Heart Hospital, Hallym University College of Medicine, Hwaseong, Republic of Korea

²Department of Neurology, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea

Corresponding author: Hee-Jin Im, M.D., Ph.D. Department of Neurology, Dongtan Sacred Heart Hospital, Hallym University Colleage of Medicine, 7 Keunjaebong-gil, Hwaseong 18450, Republic of Korea Tel: +82-31-8086-3185, Fax: +82-31-8086-2317 E-mail: coolere@naver.com

• Received: January 24, 2024 • Revised: February 29, 2024 • Accepted: March 7, 2024

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

878 Views
23 Download

Full Article

Download PDF

Abstract
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
NOTES
REFERENCES

Abstract

Purpose
Cluster headache (CH) is characterized by circadian rhythmicity of the attacks, and it is known to respond exceptionally well to oxygen therapy. Furthermore, obstructive sleep apnea (OSA) frequently co-occurs with CH, and both conditions may be parallel outcomes of hypothalamic dysfunction rather than being causally related. The aim of this study was to analyze the association between CH characteristics and polysomnographic factors stratified by the severity of OSA in patients diagnosed with CH and OSA.
Methods
We retrospectively analyzed the data of OSA patients with CH who were enrolled in the Korean Cluster Headache Registry and underwent polysomnography due to clinical suspicion of OSA. Basic demographic data, headache-related parameters, and polysomnographic parameters were analyzed according to the severity of OSA (apnea-hypopnea index: <15 or ≥15 per hour).
Results
Twelve CH patients with OSA were evaluated. The onset age of CH was higher (38.5 years vs. 19.0 years, p=0.010), and the maximal duration of cluster bouts was longer (156.5 days vs. 47.0 days, p=0.037) in the moderate-to-severe OSA group than in the mild OSA group. Unlike other polysomnographic parameters, the apnea-hypopnea index and respiratory arousal index during rapid eye movement (REM) sleep were comparable across different OSA severity levels.
Conclusion
The onset age and duration of cluster bouts were associated with the severity of OSA in CH patients. Additionally, the relatively high susceptibility to hypoxia during REM sleep in patients with mild OSA implies that interventions may be potentially advantageous, even in CH patients with mild OSA.
Keywords: Age of onset, Cluster headache, Obstructive sleep apnea, Polysomnography, REM sleep

INTRODUCTION

Cluster headache (CH) is a rare and severely disabling trigeminal autonomic cephalalgia with strong chronobiological traits.¹ CH, characterized by bouts and remission periods, can be classified as episodic or chronic. Distinguishing from other headache disorders, oxygen therapy has proven effective for rescuing CH attack.²

CH is considered one of the primary headache disorders most closely associated with sleep.³ In general, headaches and sleep are intertwined in various aspects, including clinical, physiological, epidemiological, and anatomical aspects.⁴ Evidence supports that CH attacks are more prevalent and severe during the night compared to daytime attacks in patients with periodicity (occurring at specific times during day or seasons).⁵^-⁷ Initial studies suggested that CH attacks are associated with rapid eye movement (REM) sleep, coinciding with the onset of the first REM sleep phase within 90 minutes of falling sleep. However, recent several studies have shown that CH attacks are not significantly associated with REM sleep.⁸^-¹⁰

Obstructive sleep apnea (OSA) is one of the most common sleep disorder that causes recurrent hypoxia and frequent arousal due to repeated airway collapse.¹¹ CH has been linked with sleep disordered breathing, particularly OSA. The higher prevalence of OSA (from 58%–80%) among CH patients compared to healthy controls, coupled with the increased frequency of CH attacks at night, led to the hypothesis of a potential causal relationship between these two conditions.¹²^-¹⁴ Studies conducted on CH patients showed an increased prevalence of OSA syndrome and a higher respiratory distress index during CH attack compared to healthy controls.¹⁵ However, the true relationship between CH and OSA is complex and has not been clarified yet. Currently, OSA and CH may be considered as parallel outcomes of hypothalamic dysfunction rather than a causal relationship.¹⁶

In this complex relationship between CH and sleep, our study analyzed the association of CH characteristics and polysomnographic factors stratified by OSA severity in patients with CH and diagnosed with OSA. The aim was to explore the correlation between CH and sleep, specifically focusing on their association with OSA.

MATERIALS AND METHODS

1. Ethics approval and consent to participate

All participants provided written informed consent when they enrolled in the KCHR (No. 2016-09-396). The study design was approved by the Institutional Review Board of Dongtan Sacred Heart Hospital of Hallym University and allowed of additional written informed consent to be waived due to retrospective data collection and fully anonymity (No. 2022-12-003-001). All methods were performed in accordance with the relevant guidelines and regulations.

2. Participants

This retrospective, observational single-center study included participants with CH who underwent polysomnography (PSG) on clinical suspicion of OSA at the headache clinic in the Department of Neurology of the Hallym University Dongtan Sacred Hospital (Hwaseong, Korea) between January 2020 and October 2022. CH was diagnosed by two neurologists (SJ Cho and HJ Im) based on individual interviews and the diagnostic criteria of the 3rd edition of the International Classification of Headache Disorder.¹ PSG was conducted as a level 1 sleep study (i.e., an overnight stay in a sleep laboratory with a technician in attendance)¹⁷ at the Sleep Center of Hallym University Dongtan Sacred Hospital.

The inclusion criteria for participants were as follows: 1) participation in the Korean Cluster Headache Registry (KCHR), a prospective observational study of CH,¹⁸ 2) being over 19 years of age, 3) and having undergone PSG between January 2020 and October 2022 on suspicion of OSA. The exclusion criteria were as follows: 1) PSG conducted more than 2 years after the last cluster bout, 2) failure to be diagnosed with OSA by PSG. In the 3rd edition of the International Classification of Headache Disorders,¹ CH is classified as episodic (i.e., bouts lasting from 7 days to 1 year, separated by out-of-bout periods lasting at least 3 months) or chronic (i.e., bouts lasting 1 year or longer without remission, or with out-of-bout periods lasting less than 3 months) CH, and our study investigated both episodic and chronic CH. All participants were interviewed and evaluated by trained personnel using a self-reported questionnaire.

3. Assessment of cluster headache

All participants in the KCHR completed a structured questionnaire designed for the evaluation of CH. The KCHR protocol evaluated sociodemographic variables, including sex, ages at onset and presentation, body mass index (BMI), and history of smoking and alcohol consumption. We collected the following clinical data regarding current and previous cluster bout including headache characteristics, disease duration, headache frequency (headache attacks per day), headache intensity, headache duration, diurnal rhythmicity, total number of bouts that was independent of disease duration, and presence of premorbid migraine. The following evaluations were also conducted: the Headache Impact Test-6 used for measuring the impact of a headache,¹⁹ and the visual analog scale (VAS) used for measuring the pain intensity of a headache.²⁰ The VAS score is determined by measuring the distance (mm) on the 10-cm line between the “no pain” anchor and the patient’s mark. A higher score indicates greater pain intensity.

4. Assessment of sleep factors and polysomnography data

All participants underwent laboratory nocturnal PSG (Embla^®; Natus), which entails electroencephalogram, electrooculogram, electromyogram, electrocardiogram, respiratory flow and effort, oximetry, pulse, and body position recordings. PSG data were reviewed and scored by sleep experts using the Embla RemLogic PSG Software using 30-second epochs according to the standard criteria by the American Academy of Sleep Medicine. Standard sleep indexes including total sleep time, sleep efficiency, wake after sleep onset, sleep latency, percentage of each sleep stage over total sleep time, apnea-hypopnea index (AHI, total number of apneas plus hypopneas per hour of sleep), mean oxygen saturation, lowest oxygen saturation, total arousals, and an arousal index were calculated. OSA has been defined and quantified primarily by the frequency of apneas and hypopneas during sleep. According to the International Classification of Sleep Disorders 3rd edition criteria, the severity of OSA by AHI is divided into mild (≥5 to 15 per hour), moderate (≥15 to 30 per hour), and severe (≥30 per hour).²¹ In this study, the participants were divided into two groups according to the score of AHI: a mild OSA group (AHI≥5 to 15 per hour) and a moderate to severe OSA group (AHI≥15 per hour). Sleep parameters were evaluated using a self-reported questionnaire booklet. Excessive daytime sleepiness was defined as an Epworth Sleepiness Scale score≥11.²² The likelihood of OSA was assessed by the STOP-Bang questionnaire. A score over 3 reflected a moderate risk of apnea during sleep.²³ And, insomnia symptoms were assessed using the Insomnia Severity Index, with a score>14 indicating moderate-to-severe insomnia.²⁴ Sleep quality was evaluated using the Pittsburgh Sleep Quality Index with a score>5 indicating poor sleep quality.²⁵

5. Statistical analysis

Categorical data were presented as frequencies and percentages. Continuous data, such as age, daily headache frequency, and headache intensity were presented as the median with data range (minimum to maximum). Nonparametric tests were used to establish statistical significance at p<0.05 when the normality assumption was not met. In our study, due to the small sample size and non-normal distribution of the data, group comparisons according to OSA severity were performed using nonparametric methods. Specifically, the Mann-Whitney test was used for continuous variables, and Fisher’s exact test was used for categorical variables. Data analysis was performed using SPSS version 24 (IBM Corp.).

RESULTS

1. Participants

Among 105 participants in the KCHR for 34 months, 14 participants who were clinically suspicious of OSA with CH underwent PSG. However, two participants were excluded due to being undiagnosed with OSA (AHI<5 per hour) and no cluster bout for 2 years after PSG. Ultimately, a total of 12 participants were included in our analysis (Figure 1). All participants were male, and the median age was 42 years (range, 24–62 years). The median BMI was 26.1 kg/m² (range, 21.0–32.9 kg/m²). There were 10 participants (83.3%) with episodic CH and two participants (16.7%) with chronic CH. Nine participants (75.0%) had undergone PSG during the cluster bout, and three participants had undergone PSG during the remission period. Six participants were classified for mild OSA, and the remaining participants were for moderate to severe OSA (AHI≥15 per hour). Two patients with chronic CH were classified as having moderate to severe OSA.

2. Clinical characteristics of cluster headache according to obstructive sleep apnea severity

The median disease duration of CH in all participants was 6 years (range, 1–16 years), and the median onset age of CH was 29 years (range, 15–55 years). The age at onset of CH in the moderate to severe OSA group was higher than in the mild OSA group (median, 38.5 years vs. 19.0 years; p=0.010). The maximal duration of cluster bout in the moderate to severe group (median, 156.5 days) was longer than that in the mild OSA group (median, 47.0 days; p=0.037). Other clinical features of cluster attacks including intensity, duration, and frequency did not show significant differences and were comparable between CH patients with moderate to severe OSA and those with mild OSA (Table 1). A total of 10 participants (83.3%) reported diurnal periodicity. There were no statistically significant differences in age, sex, BMI, and cardiovascular risk factors including hypertension, diabetes, hyperlipidemia, and smoking between the two groups.

3. Sleep parameters and polysomnography data features according to obstructive sleep apnea severity in cluster headache patients

In this study, most participants (n=9, 75.0%) had undergone a PSG during the cluster bout (ictal phase of CH) and no cluster attack was observed during PSG. As for the difference of OSA severity between two groups, the median value of mean oxygen saturation was 96.2% (range, 95.3%–97.4%) in the mild OSA group and 94.6% (range, 93.2%–96.2%) in the moderate to severe OSA group. There was a significant difference in AHI scores between the two groups during non-rapid eye movement (NREM) sleep, as well (4.3 vs. 19.0, p=0.004). However, there was no significant difference in AHI during REM sleep according to OSA severity (23.5 vs. 24.6, p=0.688). As a result, the REM-AHI/NREM-AHI ratio was higher in the mild group than in the moderate to severe group with borderline significance (5.8 vs. 0.9, p=0.054). Lowest saturation and longest apnea showed no significant differences between the two groups. As shown in Table 2, there was a significant difference in respiratory arousal index according to OSA severity during NREM sleep (13.4 vs. 20.9, p=0.037). During REM sleep stage, however, respiratory arousal index between two groups were comparable (14.3 vs. 14.4, p=0.872). And these results were also demonstrated in an analysis for patients who undergone PSG during the cluster bout (Figure 2). As shown in Table 2, there was no significant difference between the two groups in moderate to severe insomnia and poor sleep quality. Among the 12 patients included in the final analysis, only three patients were diagnosed with moderate to severe insomnia.

DISCUSSION

This is the first study that evaluated the characteristics of CH and polysomnographic parameters according to OSA severity in daily clinical practice using a prospective CH registry. We used single hospital data of patients with CH from the past 34 months. In the dataset 13.3% of the CH patients had undergone PSG, and 85.7% had been diagnosed with OSA. In previous study, OSA were reported to be diagnosed with PSG in 29% among the patients with CH compared to 7% among age–sex-matched healthy controls.¹⁵ Compared to the prevalence (6%–17%) of OSA in the general population, the CH population has a relatively higher prevalence in OSA, so active screen for OSA is recommended in CH patients.¹³^,²⁶

Moderate to severe OSA accounted for half of the diagnosed OSA in participants with CH in our study, which is slightly lower than the 60% reported in previous studies of CH.²⁷ Interestingly, the median onset age of CH was significantly higher in CH patients with moderate to severe OSA group than in those with mild OSA group (38.5 years vs. 19.0 years), while in the multicenter data in Korea, the mean onset age of CH was 29.3 years²⁸ and the peak onset age was around 30 years.²⁹ Because the severity of OSA depends on increasing age,²⁶ this association can be consequential a coincidence, but detrimental effect of moderate to severe OSA might have a role for occurrence of CH.³⁰^,³¹

In addition, the maximal duration of cluster bout during the follow-up period was significantly longer in CH patients with moderate to severe OSA than in those with mild OSA. Two patients with chronic CH were classified as having moderate to severe OSA. These results support the previously reported association between moderate to severe OSA and refractory or chronic CH, which was not present in mild OSA.³²^,³³ Therefore, the findings that the older onset age and the longer duration of cluster bout, the higher severity of OSA, which means that there is relationship and comorbidity, at least, between CH and OSA.

In this study, there were no differences in AHI and respiratory arousal index during the REM sleep stage according to OSA severity (Table 2, Figure 2). This indicates an increased susceptibility to hypoxia during REM sleep, especially among those with mild OSA, resulting in REM-related OSA marked by respiratory difficulties during this phase of sleep. Particularly, REM sleep in OSA patients is associated with more frequent and prolonged obstructive events, often accompanied by severe oxyhemoglobin desaturation.³⁴ This increased vulnerability during REM sleep is attributed to reduced pharyngeal muscle activity due to withdrawal of excitatory inputs to upper airway motor neurons.³⁴ Consequently, the upper airway is more prone to collapse during REM sleep in OSA patients compared to NREM sleep. Even in cases of mild OSA, REM sleep can contribute to a cycle of heightened respiratory distress and frequent arousals in patients with CH. Therefore, interventions such as positive airway pressure (PAP) therapy may be beneficial for CH patients experiencing OSA symptoms, such as excessive daytime sleepiness, snoring, or stopped breathing during sleep. Case reports³⁵^,³⁶ have demonstrated symptom improvement in CH patients following PAP therapy, suggesting its potential benefits in managing CH when OSA coexists. This underscores the importance of considering sleep-related factors in CH management.

Our study has certain limitations. First, the details about CH were collected via self-reports from the participants, which could have resulted in an over or underestimation of the true clinical characteristics of the CH attacks. Second, the sample size of this single-center study was small, so selection bias and type I or type II errors might have been committed. It is difficult to obtain large sample sized as CH patients presents with disabling pain when they visit the hospital, making it difficult to evaluate a sleep disorder and conduct laboratory PSG, especially during the cluster bout. Third, the low prevalence (11.4%) of OSA in our CH registry could have been influenced by the low performance of PSG.

It was difficult to perform sleep study for the patient, especially those during cluster bout with severe pain. However, it may have also reflected the real-world proportion of OSA evaluation by PSG among consecutive CH patients. Future studies on the appropriate indications for PSG and intervention of OSA in patients with CH are warranted. Therefore, a multicenter prospective randomized study regarding impacts on CH in patients currently using PAP as treatment of OSA is needed.

In conclusion, onset age of CH and maximal duration of cluster bout were both associated with severity of OSA in CH patients. And the relatively high susceptibility of sleep apnea during REM sleep in patients with mild OSA suggests the potential benefits of intervention even in mild severity of OSA, for CH patients. Although the relationship of OSA and CH is not causal, considering PSG examinations for comorbid OSA and can be beneficial for further management, especially in patients with CH who are elderly, experience prolonged cluster bouts, or exhibit unresponsiveness to drug treatment.

AVAILABILITY OF DATA AND MATERIAL

Anonymized data supporting the findings presented in the current study will be shared upon reasonable request from a qualified investigator.

AUTHOR CONTRIBUTIONS

Conceptualization: SJC, HJI; Data curation: YH, MKK, SJC, HJI; Formal analysis: YH, SJC, HJI; Investigation: YH, MKK, SJC, HJI; Methodology: MKC, SJC, HJI; Software: YH, SJC; Validation: MKC, SJC, HJI; Writing–original draft: YH, MKK, HJI; Writing–review and editing: YH, MKK, MKC, SJC, HJI.

CONFLICT OF INTEREST

Soo-Jin Cho is the Editor-in-Chief of Headache and Pain Research and was not involved in the review process of this article.

Soo-Kyoung Kim is the Editor of Headache and Pain Research and was not involved in the review process of this article.

Mi-Kyoung Kang is the Editor of Headache and Pain Research and was not involved in the review process of this article.

All authors have no other conflicts of interest to declare.

FUNDING STATEMENT

Not applicable.

ACKNOWLEDGMENTS

The authors thank the Clinical Research Coordinator, Jeung-Eun Kown, for study assistance.

Figure 1.

Flowchart of patient selection and evaluation.

^*One patient met both exclusion criteria.

PSG, polysomnography; OSA, obstructive sleep apnea.

Figure 2.

Comparison of polysomnographic respiratory parameters according to OSA severity in patients during cluster bouts.

*Asterisk indicates a statistically significant (p<0.05).

AHI, apnea-hypopnea index; NREM, non-rapid eye movement; REM, rapid eye movement; Resp, respiratory; ArI, arousal index; OSA, obstructive sleep apnea.

Table 1.

Clinical characteristics of cluster headache patients (n=12) according to OSA severity

Characteristic	Mild OSA (n=6)	Moderate to severe OSA (n=6)	p-value
Age (yr)	40.5 (24.0–42.0)	43.5 (34.0–62.0)	0.076
Male sex	6 (100.0)	6 (100.0)	>0.99
BMI (kg/m²)	26.6 (23.8–31.4)	26.0 (21.0–32.9)	0.631
Hypertension	1 (16.7)	3 (50.0)	0.545
Diabetes	1 (16.7)	0 (0.0)	>0.99
Hyperlipidemia	4 (66.7)	4 (66.7)	>0.99
Current smoking	3 (50.0)	5 (83.3)	0.105
Age at diagnosis of CH (yr)	28.0 (23.0–40.0)	41.5 (27.0–55.0)	0.044*
Age at onset of CH (yr)	19.0 (15.0–31.0)	38.5 (25.0–55.0)	0.010*
HIT-6 score	68.5 (63.0–78.0)	70.0 (48.0–78.0)	0.872
Maximal duration of cluster bouts (day)	47.0 (33.0–128.0)	156.5 (67.0–1,247.0)	0.037*
VAS score (headache severity)	9.0 (7.0–10.0)	9.0 (5.0–10.0)	0.672
Duration of CH attacks (min)	110.0 (30.0–180.0)	35.0 (20.0–120.0)	0.319
Frequency of CH attacks (day)	1.0 (0.5–2.5)	1.8 (1.0–2.0)	0.360
Location of CH attacks (right/left)	4 (66.7)/2 (33.3)	1 (16.7)/5 (83.3)	0.242
Presence of circadian rhythm in CH attacks	5 (83.3)	5 (83.3)	>0.99
CH attacks only at night	1 (16.7)	3 (50.0)	0.545
Presence of morning headache	1 (16.7)	1 (16.7)	>0.99
Improvement in response to oxygen therapy	1 (16.7)	4 (66.7)	0.143
Improvement in response to triptan therapy	5 (83.3)	4 (66.7)	0.211
PSG during cluster bouts	4 (66.7)	5 (83.3)	>0.99

Values are presented as median (range) or number (%).

These p-values are based on the Mann-Whitney or Fisher exact test; *Asterisk indicates a statistically significant (p<0.05).

OSA, obstructive sleep apnea; BMI, body mass index; CH, cluster headache; HIT-6, Headache Impact Test-6; VAS, visual analog scale; PSG, polysomnography.

Table 2.

Polysomnographic data and sleep parameters of cluster headache patients (n=12) according to OSA severity

Variable	Mild OSA (n=6)	Moderate to severe OSA (n=6)	p-value
Excessive sleep sleepiness	5.0 (2.0–11.0)	5.0 (2.0–15.0)	0.421
Insomnia Severity Index	10.5 (4.0–23.0)	8.5 (5.0–17.0)	0.345
Moderate to severe insomnia	2 (33.3)	1 (16.7)	0.500
Pittsburgh Sleep Quality Index	8.0 (8.0–16.0)	9.5 (8.0–14.0)	0.809
Total sleep time (min)	375.7 (350.6–420.7)	367.1 (317.5–383.3)	0.423
REM sleep (min)^†	28.8 (7.8)	30.5 (9.3)	0.423
NREM sleep (min)^†	351.3 (92.3)	328.0 (90.8)	0.423
Sleep efficiency (%)	94.4 (81.9–98.9)	95.8 (81.9–98.2)	0.936
WASO (min)	12.1 (4.0–83.0)	12.5 (6.5–70.0)	0.873
Total AHI (events/hr)	5.7 (5.0–9.4)	22.3 (16.1–53.3)	0.004*
AHI in REM (events/hr)	23.5 (0.0–30.7)	24.6 (5.3–58.5)	0.688
AHI in NREM (events/hr)	4.3 (3.4–9.4)	19.0 (14.6–56.1)	0.004*
REM/NREM-AHI ratio	5.8 (0.0–6.8)	0.9 (0.2–4.0)	0.054
Mean SpO₂ (%)	96.2 (95.3–97.4)	94.6 (93.2–96.2)	0.036*
Minimum SpO₂ (%)	90.5 (70.0–92.0)	86.5 (69.0–89.0)	0.091
Total ArI	14.1 (6.4–33.4)	21.3 (18.8–51.4)	0.037*
Resp ArI	4.6 (1.6–8.9)	14.6 (8.0–50.1)	0.004*
Total ArI in REM	16.6 (0.0–26.2)	20.0 (0.0–66.0)	0.688
Resp ArI in REM	14.3 (0.0–21.4)	14.4 (0.0–45.9)	0.872
Total ArI in NREM	13.4 (5.7–33.4)	20.9 (17.9–53.2)	0.037*
Resp ArI in NREM	3.4 (0.8–8.9)	13.4 (8.6–51.7)	0.006*

Values are presented as median (range) or number (%) unless otherwise specified.

These p-values are based on the Mann-Whitney or Fisher exact test; *Asterisk indicates a statistically significant (p<0.05). ^†These data represent the median (%).

OSA, obstructive sleep apnea; REM, rapid eye movement; NREM, non-rapid eye movement; WASO, wakefulness after sleep onset; AHI, apnea-hypopnea index; SpO2, oxygen saturation; ArI, arousal index; Resp, respiratory.

REFERENCES

1. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia 2018;38:1-211.Article PDF
2. Hoffmann J, May A. Diagnosis, pathophysiology, and management of cluster headache. Lancet Neurol 2018;17:75-83.Article PubMed
3. Evers S. Sleep and headache: the biological basis. Headache 2010;50:1246-1251.Article PubMed
4. Brennan KC, Charles A. Sleep and headache. Semin Neurol 2009;29:406-418.Article PubMed PMC
5. Pfaffenrath V, Pöllmann W, Rüther E, Lund R, Hajak G. Onset of nocturnal attacks of chronic cluster headache in relation to sleep stages. Acta Neurol Scand 1986;73:403-407.Article PubMed
6. Hagedorn A, Snoer A, Jensen R, Haddock B, Barloese M. The spectrum of cluster headache: a case report of 4600 attacks. Cephalalgia 2019;39:1134-1142.Article PubMed PDF
7. Barloese M, Lund N, Petersen A, Rasmussen M, Jennum P, Jensen R. Sleep and chronobiology in cluster headache. Cephalalgia 2015;35:969-978.Article PubMed PDF
8. Barloese M. Current understanding of the chronobiology of cluster headache and the role of sleep in its management. Nat Sci Sleep 2021;13:153-162.Article PubMed PMC PDF
9. Lund NL, Snoer AH, Jennum PJ, Jensen RH, Barloese MCJ. Sleep in cluster headache revisited: results from a controlled actigraphic study. Cephalalgia 2019;39:742-749.Article PubMed PDF
10. Terzaghi M, Ghiotto N, Sances G, Rustioni V, Nappi G, Manni R. Episodic cluster headache: NREM prevalence of nocturnal attacks. Time to look beyond macrostructural analysis? Headache 2010;50:1050-1054.Article PubMed
11. Jordan AS, McSharry DG, Malhotra A. Adult obstructive sleep apnoea. Lancet 2014;383:736-747.Article PubMed
12. Chervin RD, Zallek SN, Lin X, Hall JM, Sharma N, Hedger KM. Sleep disordered breathing in patients with cluster headache. Neurology 2000;54:2302-2306.Article PubMed
13. Graff-Radford SB, Newman A. Obstructive sleep apnea and cluster headache. Headache 2004;44:607-610.Article PubMed PDF
14. Nobre ME, Leal AJ, Filho PM. Investigation into sleep disturbance of patients suffering from cluster headache. Cephalalgia 2005;25:488-492.Article PubMed PDF
15. Evers S, Barth B, Frese A, Husstedt IW, Happe S. Sleep apnea in patients with cluster headache: a case-control study. Cephalalgia 2014;34:828-832.Article PubMed PDF
16. Graff-Radford SB, Teruel A. Cluster headache and obstructive sleep apnea: are they related disorders? Curr Pain Headache Rep 2009;13:160-163.Article PubMed PDF
17. El Shayeb M, Topfer LA, Stafinski T, Pawluk L, Menon D. Diagnostic accuracy of level 3 portable sleep tests versus level 1 polysomnography for sleep-disordered breathing: a systematic review and meta-analysis. CMAJ 2014;186:E25-E51.Article PubMed PMC
18. Cho S, Cho SJ, Lee MJ, et al. Clinical characteristics of pre-attack symptoms in cluster headache: a large series of Korean patients. Cephalalgia 2021;41:227-236.Article PubMed PDF
19. Yang M, Rendas-Baum R, Varon SF, Kosinski M. Validation of the Headache Impact Test (HIT-6™) across episodic and chronic migraine. Cephalalgia 2011;31:357-367.Article PubMed PMC PDF
20. Aicher B, Peil H, Peil B, Diener HC. Pain measurement: Visual Analogue Scale (VAS) and Verbal Rating Scale (VRS) in clinical trials with OTC analgesics in headache. Cephalalgia 2012;32:185-197.Article PubMed
21. Malhotra A, Ayappa I, Ayas N, et al. Metrics of sleep apnea severity: beyond the apnea-hypopnea index. Sleep 2021;44:zsab030.Article PubMed PMC PDF
22. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991;14:540-545.Article PubMed
23. Chung F, Abdullah HR, Liao P. STOP-Bang questionnaire: a practical approach to screen for obstructive sleep apnea. Chest 2016;149:631-638.Article PubMed
24. Bastien CH, Vallières A, Morin CM. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med 2001;2:297-307.Article PubMed
25. Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989;28:193-213.Article PubMed
26. Senaratna CV, Perret JL, Lodge CJ, et al. Prevalence of obstructive sleep apnea in the general population: a systematic review. Sleep Med Rev 2017;34:70-81.Article PubMed
27. Weintraub JR. Cluster headaches and sleep disorders. Curr Pain Headache Rep 2003;7:150-156.Article PubMed PDF
28. Chung PW, Kim BS, Park JW, et al. Smoking history and clinical features of cluster headache: results from the Korean Cluster Headache Registry. J Clin Neurol 2021;17:229-235.Article PubMed PMC PDF
29. Ofte HK, Berg DH, Bekkelund SI, Alstadhaug KB. Insomnia and periodicity of headache in an arctic cluster headache population. Headache 2013;53:1602-1612.Article PubMed
30. McDonough P, Moffatt RJ. Smoking-induced elevations in blood carboxyhaemoglobin levels. Effect on maximal oxygen uptake. Sports Med 1999;27:275-283.Article PubMed
31. Wagner PD. Muscle O2 transport and O2 dependent control of metabolism. Med Sci Sports Exerc 1995;27:47-53.Article PubMed
32. Barloese M, Jennum P, Knudsen S, Jensen R. Cluster headache and sleep, is there a connection? A review. Cephalalgia 2012;32:481-491.Article PubMed PDF
33. Nobre ME, Filho PF, Dominici M. Cluster headache associated with sleep apnoea. Cephalalgia 2003;23:276-279.Article PubMed PDF
34. Mokhlesi B, Punjabi NM. “REM-related” obstructive sleep apnea: an epiphenomenon or a clinically important entity? Sleep 2012;35:5-7.Article PubMed PMC
35. Nath Zallek S, Chervin RD. Improvement in cluster headache after treatment for obstructive sleep apnea. Sleep Med 2000;1:135-138.Article PubMed
36. Song MJ, Cho SJ, Im HJ. Improvement of nocturnal cluster headache after continuous positive airway pressure therapy in a patient with severe obstructive sleep apnea. J Sleep Med 2021;18:55-57.Article

Figure & Data

References

Citations

Citations to this article as recorded by

PubReader
ePub Link

Cite this Article

Cite this Article: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Cluster Headache Characteristics and the Severity of Obstructive Sleep Apnea: Insights from Polysomnography Analysis

Headache Pain Res. 2024;25(1):63-71. Published online April 16, 2024

DOI: https://doi.org/10.62087/hpr.2024.0001

XML Download

Figure

Cluster Headache Characteristics and the Severity of Obstructive Sleep Apnea: Insights from Polysomnography Analysis

Figure 1. Flowchart of patient selection and evaluation.*One patient met both exclusion criteria.PSG, polysomnography; OSA, obstructive sleep apnea.

Figure 2. Comparison of polysomnographic respiratory parameters according to OSA severity in patients during cluster bouts.*Asterisk indicates a statistically significant (p<0.05).AHI, apnea-hypopnea index; NREM, non-rapid eye movement; REM, rapid eye movement; Resp, respiratory; ArI, arousal index; OSA, obstructive sleep apnea.

Figure 1.

Figure 2.

Cluster Headache Characteristics and the Severity of Obstructive Sleep Apnea: Insights from Polysomnography Analysis

Characteristic	Mild OSA (n=6)	Moderate to severe OSA (n=6)	p-value
Age (yr)	40.5 (24.0–42.0)	43.5 (34.0–62.0)	0.076
Male sex	6 (100.0)	6 (100.0)	>0.99
BMI (kg/m²)	26.6 (23.8–31.4)	26.0 (21.0–32.9)	0.631
Hypertension	1 (16.7)	3 (50.0)	0.545
Diabetes	1 (16.7)	0 (0.0)	>0.99
Hyperlipidemia	4 (66.7)	4 (66.7)	>0.99
Current smoking	3 (50.0)	5 (83.3)	0.105
Age at diagnosis of CH (yr)	28.0 (23.0–40.0)	41.5 (27.0–55.0)	0.044*
Age at onset of CH (yr)	19.0 (15.0–31.0)	38.5 (25.0–55.0)	0.010*
HIT-6 score	68.5 (63.0–78.0)	70.0 (48.0–78.0)	0.872
Maximal duration of cluster bouts (day)	47.0 (33.0–128.0)	156.5 (67.0–1,247.0)	0.037*
VAS score (headache severity)	9.0 (7.0–10.0)	9.0 (5.0–10.0)	0.672
Duration of CH attacks (min)	110.0 (30.0–180.0)	35.0 (20.0–120.0)	0.319
Frequency of CH attacks (day)	1.0 (0.5–2.5)	1.8 (1.0–2.0)	0.360
Location of CH attacks (right/left)	4 (66.7)/2 (33.3)	1 (16.7)/5 (83.3)	0.242
Presence of circadian rhythm in CH attacks	5 (83.3)	5 (83.3)	>0.99
CH attacks only at night	1 (16.7)	3 (50.0)	0.545
Presence of morning headache	1 (16.7)	1 (16.7)	>0.99
Improvement in response to oxygen therapy	1 (16.7)	4 (66.7)	0.143
Improvement in response to triptan therapy	5 (83.3)	4 (66.7)	0.211
PSG during cluster bouts	4 (66.7)	5 (83.3)	>0.99

Variable	Mild OSA (n=6)	Moderate to severe OSA (n=6)	p-value
Excessive sleep sleepiness	5.0 (2.0–11.0)	5.0 (2.0–15.0)	0.421
Insomnia Severity Index	10.5 (4.0–23.0)	8.5 (5.0–17.0)	0.345
Moderate to severe insomnia	2 (33.3)	1 (16.7)	0.500
Pittsburgh Sleep Quality Index	8.0 (8.0–16.0)	9.5 (8.0–14.0)	0.809
Total sleep time (min)	375.7 (350.6–420.7)	367.1 (317.5–383.3)	0.423
REM sleep (min)^†	28.8 (7.8)	30.5 (9.3)	0.423
NREM sleep (min)^†	351.3 (92.3)	328.0 (90.8)	0.423
Sleep efficiency (%)	94.4 (81.9–98.9)	95.8 (81.9–98.2)	0.936
WASO (min)	12.1 (4.0–83.0)	12.5 (6.5–70.0)	0.873
Total AHI (events/hr)	5.7 (5.0–9.4)	22.3 (16.1–53.3)	0.004*
AHI in REM (events/hr)	23.5 (0.0–30.7)	24.6 (5.3–58.5)	0.688
AHI in NREM (events/hr)	4.3 (3.4–9.4)	19.0 (14.6–56.1)	0.004*
REM/NREM-AHI ratio	5.8 (0.0–6.8)	0.9 (0.2–4.0)	0.054
Mean SpO₂ (%)	96.2 (95.3–97.4)	94.6 (93.2–96.2)	0.036*
Minimum SpO₂ (%)	90.5 (70.0–92.0)	86.5 (69.0–89.0)	0.091
Total ArI	14.1 (6.4–33.4)	21.3 (18.8–51.4)	0.037*
Resp ArI	4.6 (1.6–8.9)	14.6 (8.0–50.1)	0.004*
Total ArI in REM	16.6 (0.0–26.2)	20.0 (0.0–66.0)	0.688
Resp ArI in REM	14.3 (0.0–21.4)	14.4 (0.0–45.9)	0.872
Total ArI in NREM	13.4 (5.7–33.4)	20.9 (17.9–53.2)	0.037*
Resp ArI in NREM	3.4 (0.8–8.9)	13.4 (8.6–51.7)	0.006*

Table 1. Clinical characteristics of cluster headache patients (n=12) according to OSA severity

Values are presented as median (range) or number (%).

These p-values are based on the Mann-Whitney or Fisher exact test; *Asterisk indicates a statistically significant (p<0.05).

OSA, obstructive sleep apnea; BMI, body mass index; CH, cluster headache; HIT-6, Headache Impact Test-6; VAS, visual analog scale; PSG, polysomnography.

Table 2. Polysomnographic data and sleep parameters of cluster headache patients (n=12) according to OSA severity

Values are presented as median (range) or number (%) unless otherwise specified.

These p-values are based on the Mann-Whitney or Fisher exact test; *Asterisk indicates a statistically significant (p<0.05). ^†These data represent the median (%).